BioCentury
ARTICLE | Company News

Corbin partners with Proteorex and U of Dundee to identify USP15 inhibitors

June 1, 2017 8:59 PM UTC

Corbin Therapeutics Inc. (Montreal, Canada) partnered with Proteorex Therapeutics Inc. (Toronto, Canada) and the University of Dundee (Dundee, U.K.) in separate deals to discover inhibitors of ubiquitin specific peptidase 15 (USP15). Corbin said USP15 may play a role in treating neuro-inflammatory diseases, including multiple sclerosis (MS).

Proteorex will use its chemistry platform to discover small molecule peptide conjugates that inhibit USP15. Corbin will have full rights to the compounds. Proteorex will receive an undisclosed upfront payment and is eligible for milestones...